Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best up and coming stocks with huge upside potential. On August 28, BofA analyst Tim Anderson raised the firm’s price target on Apogee Therapeutics to $87 from$78, while keeping a Buy rating on the shares, citing estimate changes following Q2 2025 results. The Q2 2025 financial results showed that Apogee Therapeutics had a strong cash position of $621.2 million in cash, cash equivalents, and marketable securities at the end of the quarter. The financia ...